A Phase I Study of the mTOR Inhibitor Temsirolimus Plus Capecitabine in Patients With Advanced Malignancies.
Phase of Trial: Phase I
Latest Information Update: 12 Feb 2014
At a glance
- Drugs Capecitabine (Primary) ; Temsirolimus (Primary)
- Indications Adenocarcinoma
- Focus Adverse reactions
- 11 Dec 2012 Planned end date changed from 1 Dec 2012 to 1 Jun 2013 as reported by ClinicalTrials.gov.
- 11 Dec 2012 Status changed from recruiting to active, no longer recruiting as reported by ClinicalTrials.gov.
- 30 Apr 2012 Planned end date changed from 1 Dec 2011 to 1 Dec 2012 as reported by ClinicalTrials.gov.